Gemcitabine/Dexamethasone/Cisplatin vs Cytarabine/Dexamethasone/Cisplatin for Relapsed or Refractory Aggressive-Histology Lymphoma: Cost-Utility Analysis of NCIC CTG LY.12

Matthew C. Cheung; Annette E. Hay; Michael Crump; Kevin R. Imrie; Yuyao Song; Shazia Hassan; Nancy Risebrough; Jonathan Sussman; Stephen Couban; David Macdonald; Vishal Kukreti; C. Tom Kouroukis; Tara Baetz; David Szwajcer; Pierre Desjardins; Lois Shepherd; Ralph M. Meyer; Al Le; Bingshu E. Chen; Nicole Mittmann

doi:10.1093/jnci/djv106

Gemcitabine/Dexamethasone/Cisplatin vs Cytarabine/Dexamethasone/Cisplatin for Relapsed or Refractory Aggressive-Histology Lymphoma: Cost-Utility Analysis of NCIC CTG LY.12

Matthew C. Cheung, Annette E. Hay, Michael Crump, Kevin R. Imrie, Yuyao Song, Shazia Hassan, Nancy Risebrough, Jonathan Sussman, Stephen Couban, David Macdonald, Vishal Kukreti, C. Tom Kouroukis, Tara Baetz, David Szwajcer, Pierre Desjardins, Lois Shepherd, Ralph M. Meyer, Al Le, Bingshu E. Chen, Nicole Mittmann

Pharmacology, Toxicology and Pharmaceutics

Research output: Contribution to journal › Article › peer-review

20 Citations (Scopus)

Original language	English
Journal	Journal of the National Cancer Institute
Volume	107
Issue number	7
DOIs	https://doi.org/10.1093/jnci/djv106
Publication status	Published - Jul 1 2015

ASJC Scopus Subject Areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/jnci/djv106

Cite this

Cheung, M. C., Hay, A. E., Crump, M., Imrie, K. R., Song, Y., Hassan, S., Risebrough, N., Sussman, J., Couban, S., Macdonald, D., Kukreti, V., Kouroukis, C. T., Baetz, T., Szwajcer, D., Desjardins, P., Shepherd, L., Meyer, R. M., Le, A., Chen, B. E., & Mittmann, N. (2015). Gemcitabine/Dexamethasone/Cisplatin vs Cytarabine/Dexamethasone/Cisplatin for Relapsed or Refractory Aggressive-Histology Lymphoma: Cost-Utility Analysis of NCIC CTG LY.12. Journal of the National Cancer Institute, 107(7). https://doi.org/10.1093/jnci/djv106

Gemcitabine/Dexamethasone/Cisplatin vs Cytarabine/Dexamethasone/Cisplatin for Relapsed or Refractory Aggressive-Histology Lymphoma: Cost-Utility Analysis of NCIC CTG LY.12. / Cheung, Matthew C.; Hay, Annette E.; Crump, Michael et al.
In: Journal of the National Cancer Institute, Vol. 107, No. 7, 01.07.2015.

Research output: Contribution to journal › Article › peer-review

Cheung, MC, Hay, AE, Crump, M, Imrie, KR, Song, Y, Hassan, S, Risebrough, N, Sussman, J, Couban, S, Macdonald, D, Kukreti, V, Kouroukis, CT, Baetz, T, Szwajcer, D, Desjardins, P, Shepherd, L, Meyer, RM, Le, A, Chen, BE & Mittmann, N 2015, 'Gemcitabine/Dexamethasone/Cisplatin vs Cytarabine/Dexamethasone/Cisplatin for Relapsed or Refractory Aggressive-Histology Lymphoma: Cost-Utility Analysis of NCIC CTG LY.12', Journal of the National Cancer Institute, vol. 107, no. 7. https://doi.org/10.1093/jnci/djv106

@article{d1019ef4f4874892ab48dd8824be0fb3,

title = "Gemcitabine/Dexamethasone/Cisplatin vs Cytarabine/Dexamethasone/Cisplatin for Relapsed or Refractory Aggressive-Histology Lymphoma: Cost-Utility Analysis of NCIC CTG LY.12",

author = "Cheung, {Matthew C.} and Hay, {Annette E.} and Michael Crump and Imrie, {Kevin R.} and Yuyao Song and Shazia Hassan and Nancy Risebrough and Jonathan Sussman and Stephen Couban and David Macdonald and Vishal Kukreti and Kouroukis, {C. Tom} and Tara Baetz and David Szwajcer and Pierre Desjardins and Lois Shepherd and Meyer, {Ralph M.} and Al Le and Chen, {Bingshu E.} and Nicole Mittmann",

year = "2015",

month = jul,

day = "1",

doi = "10.1093/jnci/djv106",

language = "English",

volume = "107",

journal = "Journal of the National Cancer Institute",

issn = "0027-8874",

publisher = "Oxford University Press",

number = "7",

}

TY - JOUR

T1 - Gemcitabine/Dexamethasone/Cisplatin vs Cytarabine/Dexamethasone/Cisplatin for Relapsed or Refractory Aggressive-Histology Lymphoma

T2 - Cost-Utility Analysis of NCIC CTG LY.12

AU - Cheung, Matthew C.

AU - Hay, Annette E.

AU - Crump, Michael

AU - Imrie, Kevin R.

AU - Song, Yuyao

AU - Hassan, Shazia

AU - Risebrough, Nancy

AU - Sussman, Jonathan

AU - Couban, Stephen

AU - Macdonald, David

AU - Kukreti, Vishal

AU - Kouroukis, C. Tom

AU - Baetz, Tara

AU - Szwajcer, David

AU - Desjardins, Pierre

AU - Shepherd, Lois

AU - Meyer, Ralph M.

AU - Le, Al

AU - Chen, Bingshu E.

AU - Mittmann, Nicole

PY - 2015/7/1

Y1 - 2015/7/1

UR - http://www.scopus.com/inward/record.url?scp=84938099548&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938099548&partnerID=8YFLogxK

U2 - 10.1093/jnci/djv106

DO - 10.1093/jnci/djv106

M3 - Article

C2 - 25868579

AN - SCOPUS:84938099548

SN - 0027-8874

VL - 107

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

IS - 7

ER -

Gemcitabine/Dexamethasone/Cisplatin vs Cytarabine/Dexamethasone/Cisplatin for Relapsed or Refractory Aggressive-Histology Lymphoma: Cost-Utility Analysis of NCIC CTG LY.12

ASJC Scopus Subject Areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this